ライフサイエンスコーパス: muscle spasm

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 sponsible for the crotamine-induced skeletal muscle spasm.

2 SCI restoration of neuronal excitability and muscle spasms.

3 drug-related adverse effects, most commonly muscle spasms (12 patients), weight loss (10), dysgeusia

4 y, patients receiving etelcalcetide had more muscle spasms (12.0% and 11.1% vs 7.1% and 6.2% with pla

5 differences between arms (PAG v AG) included muscle spasms (13% v 1%), neutropenia (29% v 18%), and m

6 in 491 (98%) patients; the most common were muscle spasms (317 [64%]), alopecia (307 [62%]), dysgeus

7 ents of any grade were diarrhoea (48 [66%]), muscle spasms (45 [62%]), and fatigue (41 [56%]).

8 adelpar 50 mg and one on seladelpar 200 mg), muscle spasms (8%; three patients on seladelpar 200 mg),

9 is characterised by progressive rigidity and muscle spasms affecting the axial and limb muscles.

10 ons, opening up new targets for treatment of muscle spasms after SCI.

11 nes are used for treating anxiety, epilepsy, muscle spasm, alcohol withdrawal, palliation, insomnia,

12 occurring in more than 30% of patients were muscle spasms, alopecia, dysgeusia (taste disturbance),

13 CT scanning to minimize the degree of smooth-muscle spasm and peristalsis and to reduce the patient's

14 ctomy would create a prolonged inhibition of muscle spasm and postoperative pain, facilitating tissue

15 g/kg per day [0.0-14.8]; p=0.005) to control muscle spasms and associated tachycardia.

16 chanical ventilation and improves control of muscle spasms and autonomic instability.

17 assisted ventilation and of drugs to control muscle spasms and cardiovascular instability within the

18 e the requirement for other drugs to control muscle spasms and cardiovascular instability.

19 the patient exhibits unusual signs, such as muscle spasms and fever.

20 ions of cannabis in the treatment of painful muscle spasms and other symptoms of multiple sclerosis a

21 3-20 Hz correlated with the strength of the muscle spasms and preceded them by approximately 320 ms.

22 ith fatigue, two with hyponatremia, one with muscle spasm, and one with atrial fibrillation.

23 tients were back pain, arthralgia, headache, muscle spasms, and pain in extremity (all <2%).

24 In addition, acute muscle spasms associated with oxaliplatin were significa

25 s also useful for treatment of spasticity or muscle spasms associated with several clinical condition

26 worse treatment-related adverse events were muscle spasms (four [4%] patients in treatment group A v

27 aemia, and strokes with anastrozole and more muscle spasm, gynaecological cancers and symptoms, vasom

28 s characterized by muscle rigidity, episodic muscle spasms, high titers of antibodies against glutami

29 clonus is characterized by rigidity, painful muscle spasms, hyperekplexia, and brainstem signs.

30 e as free doxorubicin injections in reducing muscle spasms in blepharospasm patients but with increas

31 ion, anxiety, mood swings, severe headaches, muscle spasms, interphalangeal joint stiffness, decrease

32 ommon adverse events were fatigue, diarrhea, muscle spasms, nausea, and bruising.

33 s in the placebo group), with hypocalcaemia, muscle spasm, paraesthesias, headache, and nausea being

34 s (muscle stiffness, pain and discomfort and muscle spasms,), physical impact (activities of daily li

35 the number of injections needed for patient muscle spasm relief, decreasing the risk of negative sid

36 f baclofen on spasticity (e.g. management of muscle spasms that may otherwise hinder movement or soci

37 Muscle spasms, the most frequent adverse event in the ba

38 Dystonic involuntary muscle spasms were specifically associated with increase

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。